WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No. 333-280414) on June 21, 2024, which was declared effective by the Securities and Exchange Commission on August 2, 2024, to register the issuance of earnout shares and shares un ...

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

We are pleased to share our progress and next steps that underscore our commitment to advancing science to benefit patients and physicians while supporting our stockholder's investment. We are also happy to share that since its inception, Tevogen.AI has made strides in its mission to enhance drug discovery through predictive modeling. About Tevogen Bio Forward-Looking Statements You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertak ...

We are also happy to share that since its inception, Tevogen.AI has made strides in its mission to enhance drug discovery through predictive modeling. We continue to emphasize our achievements, highlighting that our cost-effective business model has been instrumental in driving this level of progress. Independent equity research has initiated coverage echoing this sentiment. In light of recent stock performance, we understand the concerns some of you may have regarding Tevogen Bio's current share price. We ...

Dr. Lori Grosso, Clinical Development Lead, spoke to advances made with genetically modified T cell therapies but noted that patient affordability, tolerability, and accessibility barriers have prevented broader adoption. She noted that unlike genetically modified autologous T cells which produce one treatment dose per patient, Tevogen's ExacTcell platform produced hundreds of doses from a single donor for its successful phase I clinical trial. In terms of safety, this trial, the results of which were recen ...

"I share Marc's belief that business success must coexist with social prosperity," said Dr. Ryan Saadi. "As a Yale graduate and a member of the Yale School of Public Health Leadership Council, it was a distinct pleasure to join Yale School of Management Senior Associate Dean, Jeffrey Sonnenfeld and business pioneers including Nikesh Arora, CEO, Palo Alto Networks; Steven Bandrowczak, CEO, Xerox; Ivan Seidenberg, Former Chair & CEO, Verizon; Brian Moynihan, Chair & CEO, Bank of America; Ken Moelis, Founder, ...

"I share Marc's belief that business success must coexist with social prosperity," said Dr. Ryan Saadi. "As a Yale graduate and a member of the Yale School of Public Health Leadership Council, it was a distinct pleasure to join Yale School of Management Senior Associate Dean, Jeffrey Sonnenfeld and business pioneers including Nikesh Arora, CEO, Palo Alto Networks; Steven Bandrowczak, CEO, Xerox; Ivan Seidenberg, Former Chair & CEO, Verizon; Brian Moynihan, Chair & CEO, Bank of America; Ken Moelis, Founder, ...